Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Hepatology · Acute Hepatic Porphyria

Long-Term Health Risks and Liver Surveillance

At a Glance

Acute Hepatic Porphyria (AHP) is a chronic disease requiring lifelong monitoring for silent complications. Patients over 50 need liver scans every 6 to 12 months to screen for liver cancer, alongside regular monitoring for kidney disease, high blood pressure, and chronic nerve damage.

Managing Acute Hepatic Porphyria (AHP) is a lifelong commitment that goes beyond just surviving the next attack. Because the neurotoxic chemicals (ALA and PBG) can cause cumulative damage, AHP is now recognized as a chronic, multisystem disease [1][2]. Staying engaged with your medical team—even during long periods without an attack—is essential for monitoring “silent” risks to your liver, kidneys, and nervous system.

The High Risk of Liver Cancer

One of the most critical long-term risks for people with AHP is Hepatocellular Carcinoma (HCC), a type of primary liver cancer [3][4].

  • The Unique Risk: Unlike most other conditions where liver cancer only occurs after severe scarring (cirrhosis), HCC in AHP patients can develop in a liver that otherwise looks healthy [5].
  • Who is at Risk? The risk is highest for those over the age of 50, particularly women with Acute Intermittent Porphyria (AIP) [5][4].
  • Surveillance Guidelines: Expert consensus recommends radiological surveillance (usually an ultrasound, MRI, or CT scan) every 6 to 12 months for all AHP patients starting at age 50 [4]. This screening is vital because early detection significantly improves the success of treatment.

Chronic Kidney Disease and Hypertension

Your kidneys are also vulnerable to the long-term effects of porphyria [6].

  • Kidney Damage: Chronic exposure to porphyrin precursors can lead to Porphyria-Associated Kidney Disease [1]. Over time, this may progress to chronic kidney disease (CKD), which requires regular monitoring of your eGFR (a measure of kidney function) [7].
  • High Blood Pressure: Chronic hypertension (high blood pressure) is very common in AHP patients [6]. It can be a “silent” complication that strains both your heart and kidneys. Managing your blood pressure with porphyria-safe medications is a cornerstone of long-term health [1][8].

Chronic Pain and Nerve Health

For many, the pain of porphyria doesn’t completely disappear between attacks [2][9].

  • Neuropathy: Recurrent attacks can cause “axonal damage”—essentially scarring of the nerves—which leads to chronic weakness, numbness, or persistent pain [10][1].
  • The Burden of Illness: This “inter-attack” pain can significantly impact your quality of life, mood, and ability to work [11][2]. Modern preventative treatments, such as Givosiran, have been shown to not only prevent attacks but also reduce this chronic symptom burden and the need for long-term opioid use [12][13].

Your Long-Term Health Checklist

To protect your health over the decades, ensure your care plan includes these regular checks:

Complication Screening Test Frequency
Liver Cancer (HCC) Liver Ultrasound, MRI, or CT Every 6–12 months (starting at age 50) [4].
Kidney Disease Serum Creatinine and eGFR At least annually [1].
Hypertension Blood Pressure Check At every doctor’s visit [8].
Nerve Damage Neurological Exam Annually or if new weakness appears [10].

By staying proactive with these screenings, you and your care team can catch potential issues early, ensuring that your life with porphyria is as healthy and stable as possible [14][9].

Return to Home

Common questions in this guide

Why do I need liver scans if my liver blood tests are normal?
In people with Acute Hepatic Porphyria, liver cancer can develop even if the liver otherwise looks healthy and has no severe scarring or cirrhosis. Regular imaging scans are required to catch cancer early, as standard blood tests alone may not detect it.
How often should I be screened for liver cancer with AHP?
Expert guidelines recommend that all patients with Acute Hepatic Porphyria start receiving radiological surveillance every 6 to 12 months beginning at age 50. This typically involves a liver ultrasound, MRI, or CT scan.
Can porphyria cause long-term kidney problems?
Yes, chronic exposure to the chemicals produced during porphyria attacks can lead to Porphyria-Associated Kidney Disease over time. Patients should have their kidney function (eGFR) and blood pressure checked at least annually.
Is it normal to have persistent pain between porphyria attacks?
Recurrent porphyria attacks can cause scarring of the nerves, leading to chronic weakness, numbness, or persistent pain that remains even when you are not actively having an attack. Preventative treatments can help reduce this chronic symptom burden.
What specific tests are needed to monitor long-term health with AHP?
A comprehensive long-term care plan should include annual kidney function tests (eGFR), frequent blood pressure checks, periodic neurological exams, and bi-annual to annual liver imaging for patients over 50.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.I am over 50; can we schedule my annual liver ultrasound or MRI to screen for HCC?
  2. 2.Since HCC in porphyria can happen without cirrhosis, why is it important for me to have regular scans even if my liver blood tests are normal?
  3. 3.How often should we be checking my kidney function (eGFR) and blood pressure to monitor for long-term complications?
  4. 4.I still have pain between attacks; can we check my 'porphyria-safe' pain management plan to ensure we are protecting my nerves?
  5. 5.Are there any specific liver risk factors, like fatty liver or Hepatitis C, that we should screen for to reduce my overall cancer risk?
  6. 6.Can we check my vitamin status and homocysteine levels, especially if we are considering long-term treatment with Givosiran?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Long-term complications in acute porphyria.

    Pischik E, Lissing M, Pallet N, Kauppinen R

    Liver international : official journal of the International Association for the Study of the Liver 2024; (44(9)):2197-2207 doi:10.1111/liv.15966.

    PMID: 38819621
  2. 2

    Patient Perspective on Acute Hepatic Porphyria with Sporadic Attacks: A Chronic Disease with Substantial Health-Related Quality of Life Impacts.

    Wheeden K, Lyon Howe D, Burrell S, et al.

    Advances in therapy 2022; (39(9)):4330-4345 doi:10.1007/s12325-022-02172-8.

    PMID: 35907153
  3. 3

    Acute hepatic porphyria and cancer risk: a nationwide cohort study.

    Baravelli CM, Sandberg S, Aarsand AK, et al.

    Journal of internal medicine 2017; (282(3)):229-240 doi:10.1111/joim.12646.

    PMID: 28730628
  4. 4

    Hepatocellular carcinoma in acute hepatic porphyrias: A Damocles Sword.

    Peoc'h K, Manceau H, Karim Z, et al.

    Molecular genetics and metabolism 2019; (128(3)):236-241 doi:10.1016/j.ymgme.2018.10.001.

    PMID: 30413387
  5. 5

    Hepatocellular Carcinoma in Acute Hepatic Porphyria: A Meta-Analysis of Observational Studies.

    Singal AK, Reddy RK, Gudiwada MC, et al.

    Digestive diseases and sciences 2024; (69(11)):4268-4274 doi:10.1007/s10620-024-08661-w.

    PMID: 39438413
  6. 6

    Risk for incident comorbidities, nonhepatic cancer and mortality in acute hepatic porphyria: A matched cohort study in 1244 individuals.

    Lissing M, Vassiliou D, Floderus Y, et al.

    Journal of inherited metabolic disease 2023; (46(2)):286-299 doi:10.1002/jimd.12583.

    PMID: 36546345
  7. 7

    A Delayed Progression of Porphyria-Associated Kidney Disease After Hemin Therapy in a Patient with Acute Intermittent Porphyria: A Case Report.

    Ishimura T, Wells KJ, Shimada A, et al.

    Internal medicine (Tokyo, Japan) 2026; doi:10.2169/internalmedicine.7131-26.

    PMID: 42144323
  8. 8

    Therapeutic approach to acute crises of hepatic porphyrias.

    Garrido Montes M, Pertusa Mataix R, Garcia Morillo JS

    Revista clinica espanola 2024; (224(10)):664-669 doi:10.1016/j.rceng.2024.09.004.

    PMID: 39313028
  9. 9

    Homocysteine elevation in givosiran treatment: Suggested ALAS1 siRNA effect on cystathionine beta-synthase.

    Vassiliou D, Sardh E

    Journal of internal medicine 2021; (290(4)):928-930 doi:10.1111/joim.13341.

    PMID: 34184789
  10. 10

    Neurofilament light chain as a biomarker for acute hepatic porphyrias.

    Sgobbi P, Serrano PL, Badia BML, et al.

    Frontiers in neurology 2024; (15()):1384678 doi:10.3389/fneur.2024.1384678.

    PMID: 38715693
  11. 11

    Patient and caregiver experiences of living with acute hepatic porphyria in the UK: a mixed-methods study.

    Gill L, Burrell S, Chamberlayne J, et al.

    Orphanet journal of rare diseases 2021; (16(1)):187 doi:10.1186/s13023-021-01816-2.

    PMID: 33902669
  12. 12

    Patient experience with acute hepatic porphyria before and after long-term givosiran treatment in a qualitative interview study.

    Naik H, Brown M, Meninger S, Lombardelli S

    Molecular genetics and metabolism reports 2025; (42()):101174 doi:10.1016/j.ymgmr.2024.101174.

    PMID: 39811158
  13. 13

    Givosiran: a targeted treatment for acute intermittent porphyria.

    Dickey AK, Leaf RK

    Hematology. American Society of Hematology. Education Program 2024; (2024(1)):426-433 doi:10.1182/hematology.2024000663.

    PMID: 39644007
  14. 14

    Liver transplantation and primary liver cancer in porphyria.

    Lissing M, Wang B, Wahlin S

    Liver international : official journal of the International Association for the Study of the Liver 2025; (45(3)):e15894 doi:10.1111/liv.15894.

    PMID: 38456621

This page provides information on long-term surveillance for Acute Hepatic Porphyria for educational purposes only. Always consult your hepatologist, neurologist, or primary care physician to determine the appropriate screening schedule for your specific health needs.

Get notified when new evidence is published on Porphyria.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.